Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 13;4(10):664-667.
doi: 10.1016/j.medj.2023.07.007.

Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients

Timothée Bruel  1 , Lou-Léna Vrignaud  2 , Françoise Porrot  3 , Isabelle Staropoli  3 , Delphine Planas  4 , Florence Guivel-Benhassine  3 , Julien Puech  5 , Matthieu Prot  6 , Sandie Munier  6 , William Henry Bolland  7 , Cathia Soulié  8 , Karen Zafilaza  8 , Clovis Lusivika-Nzinga  9 , Marie-Laure Meledge  9 , Céline Dorival  9 , Diana Molino  10 , Hélène Péré  11 , Youri Yordanov  12 , Etienne Simon-Lorière  13 , David Veyer  11 , Fabrice Carrat  14 , Olivier Schwartz  4 , Anne-Geneviève Marcelin  8 , Guillaume Martin-Blondel  15 ; ANRS 0003S CoCoPrev Study Group  10
Collaborators, Affiliations

Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients

Timothée Bruel et al. Med. .

Abstract

Antibodies effective against the recent Omicron sublineages are missing. By taking advantage of a multi-centric prospective cohort of immunocompromised individuals treated for mild-to-moderate COVID-19, Bruel et al. show that administration of 500 mg of sotrovimab induces serum neutralization and antibody-dependent cellular cytotoxicity of BQ.1.1 and XBB.1.5. Therefore, sotrovimab may remain a therapeutic option against these variants.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest T.B. and O.S. have a pending patent application for an anti-RBD mAb not used in this study (PCT/FR2021/070522).

References

    1. Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S, Watanabe S, Suzuki T, Maeda K, Sakai-Tagawa Y, et al. (2022). Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB. New Engl J Med 388, 89–91. 10.1056/nejmc2214302. - DOI - PMC - PubMed
    1. Wu MY, Carr EJ, Harvey R, Mears HV, Kjaer S, Townsley H, Hobbs A, Ragno M, Herman LS, Adams L, et al. (2023). WHO’s Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed. Lancet Lond Engl 400, 2193–2196. 10.1016/s0140-6736(22)01938-9. - DOI - PMC - PubMed
    1. Mazzaferri F, Mirandola M, Savoldi A, Nardo PD, Morra M, Tebon M, Armellini M, Luca GD, Calandrino L, Sasset L, et al. (2022). Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern. Elife 11, e79639. 10.7554/elife.79639. - DOI - PMC - PubMed
    1. Zheng B, Green ACA, Tazare J, Curtis HJ, Fisher L, Nab L, Schultze A, Mahalingasivam V, Parker EPK, Hulme WJ, et al. (2022). Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform. Bmj 379, e071932. 10.1136/bmj-2022-071932. - DOI - PMC - PubMed
    1. Schmidt P, Narayan K, Li Y, Kaku CI, Brown ME, Champney E, Geoghegan JC, Vásquez M, Krauland EM, Yockachonis T, et al. (2023). Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers. Sci Transl Med 15, eadg2783. 10.1126/scitranslmed.adg2783. - DOI - PubMed

Publication types

MeSH terms